Efficacy and safety of inclisiran based on background lipid-lowering treatment
Sustained and effective LDL-C lowering with inclisiran was observed irrespective of background LLT treatment. Inclisiran was overall well tolerated with all background LLT treatments, consistent with its established safety profile.
Authors
- Kausik Kumar Ray (ORCID: https://orcid.org/0000-0003-0508-0954)
- R Scott Wright
- Wolfgang Köenig (ORCID: https://orcid.org/0000-0002-2064-9603)
- Frederick Johan Raal (ORCID: https://orcid.org/0000-0002-9170-7938)
- Gregory G. Schwartz (ORCID: https://orcid.org/0000-0003-2954-0695)
- Lorena Garcia Conde (ORCID: https://orcid.org/0009-0001-9894-1743)
- Lawrence A. Leiter (ORCID: https://orcid.org/0000-0002-1040-6229)
- Ulf Landmesser (ORCID: https://orcid.org/0000-0002-0214-3203)
- Jackie Han
Institutions
- Novartis (Switzerland) (CH)
- University of Toronto (CA)
- University of the Witwatersrand (ZA)
- Universität Ulm (DE)
- Deutsches Herzzentrum der Charité (DE)
- NIHR Imperial Biomedical Research Centre (GB)
- Zimmer Biomet (United States) (US)
- Mayo Clinic in Arizona (US)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Deutsches Herzzentrum München (DE)
- Tris Pharma (United States) (US)
- Imperial College London (GB)
- Technical University of Munich (DE)
- University of Colorado Denver (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1093/eurjpc/zwaf214
- Citations
- 5
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 10.03
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Medicines Company
- Kowa Company
- Singulex
- Novo Nordisk
- Esperion Therapeutics
- Genentech
- Novartis Pharma
- Daiichi Sankyo Europe